Clinical Trial Search block Test

SC-0096: SNDX-5613-0707: Expanded Access Program for SNDX-5613 in Patients with Relapsed/Refractory Acute Leukemias with Genetic Alterations Associated with HOXA Overexpression

SC-0096

  • Condition(s): Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Infant Leukemia, Leukemia & Lymphoma, Recurrent and/or Refractory
  • Phase: N/A
  • Clinicaltrials.gov ID: NCT05918913

What is the goal of the study?

This is a multi-site, open-label EAP intended to provide early access to treatment with SNDX-5613 for patients with R/R leukemias, including those harboring an MLL/KMT2A gene rearrangement, NUP98, NPM1c mutation, or any other genetic alteration with overexpression of HOXA genes predicted to potentially respond to menin inhibitors, who are not eligible for a clinical study, have no other treatment options, and, in the opinion of the treating physician, would potentially benefit from treatment with SNDX-5613. Patients who are currently being treated with SNDX-5613 through a Syndax-sponsored clinical trial and have successfully completed the requirements of the clinical trial may also be considered for this EAP.

Who can participate in the study?

Everyone

Study Team: